Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
University of St Andrews, Fife, UK.
Transfusion. 2021 Jan;61(1):57-71. doi: 10.1111/trf.16134. Epub 2020 Oct 20.
Platelet transfusions are used to prevent or control bleeding in patients with thrombocytopenia or platelet dysfunction. The pretransfusion platelet count threshold has been studied extensively in multiple patient settings yielding high-quality evidence that has been summarized in several comprehensive evidence-based platelet guidelines.
A prospective 12-week audit of consecutive platelet transfusions using validated and evidence-based adjudication criteria was conducted. Patient demographic, laboratory, and transfusion details were collected with an electronic audit tool. Each order was adjudicated either electronically or independently by two transfusion medicine physicians. The aim was to determine platelet transfusion appropriateness and common scenarios with deviations from guidelines.
Fifty-seven (38%) of 150 hospitals provided data on 1903 platelet orders, representing 90% of platelet usage in the region during the time period. Overall, 702 of 1693 adult (41.5%) and 133 of 210 pediatric orders (63.3%) were deemed inappropriate. The most common inappropriate platelet order was for prophylaxis in the absence of bleeding or planned procedure in patients with hypoproliferative thrombocytopenia and a platelet count over 10 x 10 /L (53% of inappropriate orders in adults and 45% in pediatrics). Platelet transfusions ordered with either a preprinted transfusion order set (odds ratio [OR], 1.97; 95% confidence interval [CI], 1.44-2.73) or technologist prospective screening (OR, 1.40; 95% CI, 1.10-1.78) were more likely to be appropriate.
There is a discrepancy between clinical practice and evidence-based platelet guidelines. Broad educational and system changes will be needed to align platelet transfusion practice with guideline recommendations.
血小板输注用于预防或控制血小板减少症或血小板功能障碍患者的出血。在多种患者环境中,已经广泛研究了输血前血小板计数阈值,产生了高质量的证据,并在几个基于证据的综合血小板指南中进行了总结。
对连续血小板输注进行了为期 12 周的前瞻性审核,使用了经过验证和基于证据的裁决标准。使用电子审核工具收集患者的人口统计学、实验室和输血详细信息。每个订单都通过电子方式或由两名输血医学医师独立裁决。目的是确定血小板输血的适宜性以及与指南偏离的常见情况。
57 家(38%)150 家医院提供了 1903 个血小板订单的数据,代表了该地区在此期间血小板使用量的 90%。总体而言,1693 个成人(41.5%)中的 702 个和 210 个儿科(63.3%)订单被认为是不适当的。最常见的不适当血小板订单是在无出血或计划手术的情况下,对增生性血小板减少症和血小板计数超过 10×10/L 的患者进行预防(成人中 53%的不适当订单和儿科中 45%)。使用预印输血医嘱集(比值比 [OR],1.97;95%置信区间 [CI],1.44-2.73)或技术员前瞻性筛查(OR,1.40;95%CI,1.10-1.78)下达的血小板输注更可能是适当的。
临床实践与基于证据的血小板指南之间存在差异。需要广泛的教育和系统改变,以使血小板输血实践与指南建议保持一致。